Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress – Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support...